- Home
- KBR vs LEGN Comparison
KBR vs LEGN Comparison
Compare KBR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KBR | LEGN |
|---|---|---|
| Founded | 1901 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 3.6B |
| IPO Year | 2006 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KBR | LEGN |
|---|---|---|
| Price | $35.05 | $19.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 13 |
| Target Price | $44.29 | ★ $46.90 |
| AVG Volume (30 Days) | 1.2M | ★ 1.7M |
| Earning Date | 10-29-2026 | 11-11-2026 |
| Dividend Yield | ★ 1.88% | N/A |
| EPS Growth | ★ 15.05 | N/A |
| EPS | ★ 1.55 | N/A |
| Revenue | ★ $5,767,000,000.00 | N/A |
| Revenue This Year | $3.48 | $39.04 |
| Revenue Next Year | $5.59 | $25.29 |
| P/E Ratio | $22.74 | ★ N/A |
| Revenue Growth | ★ 2.27 | N/A |
| 52 Week Low | $29.94 | $16.24 |
| 52 Week High | $48.13 | $37.50 |
Technical Indicators
Market Signals| Indicator | KBR | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 49.26 | 51.01 |
| Support Level | $35.91 | $17.81 |
| Resistance Level | $38.36 | $20.39 |
| Average True Range (ATR) | 0.92 | 0.77 |
| MACD | -0.03 | 0.25 |
| Stochastic Oscillator | 60.57 | 88.36 |
Price Performance
Historical ComparisonAbout KBR KBR Inc.
KBR, formerly Kellogg Brown & Root, is a global provider of technology, integrated engineering, procurement, and construction delivery, and operations and maintenance services. The company's business is organized into two segments: mission technology solutions and sustainable technology solutions. KBR has operations in over 30 countries and employs approximately 36,000 people. The firm generated $7.8 billion in revenue in 2025.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.